The short answer
Retatrutide is supplied lyophilised and is most stable dry, cold and dark. Its fatty-acid chain makes it amphipathic and therefore more surface-active than an unmodified peptide, which makes gentle reconstitution and avoiding foam more consequential than usual.
Key facts
- Supplied as
- White lyophilised powder
- Distinguishing feature
- Amphipathic (C20 lipid chain)
- Main handling risk
- Interface denaturation
- Visible warning
- Foaming
- Storage
- Cold, dry, dark
- Freeze-thaw
- Avoid by aliquoting
Why lyophilised is the stable state
Water participates in peptide-bond hydrolysis and enables the oxidation and deamidation chemistry that degrades specific residues. Freeze-drying removes it. This applies to every peptide, and the general case is set out in the peptide reference category. What follows is what is specific to a lipidated 39-mer.
The surface-activity problem
All peptides denature at air-liquid interfaces. A lipidated peptide is worse, because the hydrophobic tail actively drives the molecule to that interface rather than merely allowing it to arrive. Shaking a lipidated peptide is therefore more damaging than shaking an unmodified one, and foam (the visible evidence of interface creation) is a stronger signal here.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Reconstitution technique
Introduce diluent gently down the vial wall rather than directing it onto the cake, and swirl rather than shake. Allow time: a 39-residue lipidated peptide dissolves more slowly than a short hydrophilic one, and the instinctive response to slow dissolution, more agitation, is the wrong one.
Why aggregation is the failure mode to watch
Amphipathic molecules self-associate above a threshold concentration, and an unfolded lipidated peptide aggregates readily. Cloudiness or particulates in a solution that was previously clear indicates this has happened, and aggregated material is not recoverable by further mixing.
After reconstitution
Aliquot into single-use volumes. Freeze-thaw cycling concentrates solutes at the advancing ice boundary and creates fresh interfaces on each cycle, and interfaces are what this molecule tolerates least. The general advice applies with more force here than for the short peptides elsewhere in this library.
A note on what is being handled
Material supplied for laboratory research is not the compound administered in the TRIUMPH trials, which is manufactured, formulated and handled under clinical standards. Storage guidance here concerns preserving a research material's chemical integrity, nothing more.
Frequently asked questions
Why does foaming matter more for retatrutide?
Its fatty-acid chain makes it amphipathic, which actively drives it to air-liquid interfaces where peptides unfold and then aggregate.
What if it dissolves slowly?
Allow time and swirl gently. A lipidated 39-mer dissolves more slowly than a short hydrophilic peptide, and more agitation makes things worse.
What does cloudiness indicate?
Aggregation, which amphipathic molecules are prone to. It is not recoverable by further mixing.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubMedStability of protein pharmaceuticals: an update. Pharm Res (PMID 20143256)pubmed.ncbi.nlm.nih.gov
- PubMedNail SL et al., Fundamentals of freeze-drying. Pharm Biotechnol 2002 (PMID 12189727)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Retatrutide Molecular Weight4,731.33 Da is the figure everyone quotes. It comes from supplier sources rather than a primary database, and at least one reference gives a different formula.
- Retatrutide in the Published LiteratureA small literature of unusually high quality - Cell Metabolism, NEJM, the Lancet - and a Phase 3 programme of more than 5,800 participants.
- What Is the TRIUMPH Trial Programme?TRIUMPH is Eli Lilly's Phase 3 programme for retatrutide: 5,800+ participants. TRIUMPH-1 reported 28.3% mean weight reduction at 80 weeks in May 2026.
- How One Peptide Engages Three ReceptorsGIPR, GLP-1R and GCGR belong to one receptor family, which is what makes a single-molecule triple agonist possible at all.
- Retatrutide and AlcoholNo interaction study exists for retatrutide specifically. What the GLP-1 class literature reports about alcohol, and why the honest answer is narrow.